W. Shaw Robert
Known title: DirectorCIK: 0001493772
W. Shaw Robert's purchase track record
How the stock did after each of W. Shaw Robert's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since February 7, 2022
Stock higher 6 months later
40%
3 months: 40%
Median 6-month return
-1.8%
3 months: -5.5%
Beat the S&P 500
40%
median -11.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2025 | ULBI | $10K | +3.0% | +21.6% | +12.1% |
| 5/14/2025 | ULBI | $22K | +24.1% | +4.3% | +16.3% |
| 11/12/2024 | ULBI | $20K | -6.9% | -31.0% | -1.6% |
| 9/14/2023 | ULBI | $21K | -27.2% | -12.6% | +14.3% |
| 2/7/2022 | ULBI | $15K | -5.5% | -1.8% | -7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ULBI | ▲ Buy | Open Market | 1,750 | $10K | 11/24/2025 | View on chart |
| ULBI | ▲ Buy | Open Market | 4,000 | $22K | 5/14/2025 | View on chart |
| ULBI | ▲ Buy | Open Market | 2,500 | $20K | 11/12/2024 | View on chart |
| ULBI | ▲ Buy | Open Market | 2,000 | $21K | 9/14/2023 | View on chart |
| ULBI | ▲ Buy | Open Market | 3,000 | $15K | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ultralife Upgraded to Neutral on Backlog and Product Progress
Ultralife Corporation received an upgrade to a Neutral rating, driven by its current backlog and progress in commercializing new products. This analyst action suggests improved confidence in the company's operational outlook. The stock is currently trading within its 52-week range, with recent technical signals indicating interaction with key support levels.
Ultralife Upgraded to Neutral on Backlog and Product Progress. Ultralife Corporation received an upgrade to a Neutral rating, driven by its current backlog and progress in commercializing new products. This analyst action suggests improved confidence in the company's operational outlook. The stock is currently trading within its 52-week range, with recent technical signals indicating interaction with key support levels.